Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus.

MLA

Rehman, Saad U., and Faiqa Rahman. “Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus.” Cureus, vol. 12, no. 8, Aug. 2020, p. e9655. EBSCOhost, https://doi.org/10.7759/cureus.9655.

APA

Rehman, S. U., & Rahman, F. (2020). Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus. Cureus, 12(8), e9655. https://doi.org/10.7759/cureus.9655

Chicago

Rehman, Saad U, and Faiqa Rahman. 2020. “Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus.” Cureus 12 (8): e9655. doi:10.7759/cureus.9655.